<DOC>
	<DOCNO>NCT00302861</DOCNO>
	<brief_summary>This multi-center , open-label , single arm Phase 1/2 study evaluate feasibility , safety , tolerability series 16 immunization Id-KLH GM-CSF patient previously untreated B-CLL . The length control portion study two year . The study conduct investigative site United States .</brief_summary>
	<brief_title>A Study Evaluate Treatment Previously Untreated B-Cell Chronic Lymphocytic Leukemia ( B-CLL )</brief_title>
	<detailed_description />
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Leukemia , Lymphocytic , Chronic , B-Cell</mesh_term>
	<criteria>Have sign write informed consent BCLL diagnosis Rai Stage 0 , I , II Previously untreated Be able watch wait approximately 8 month follow submission blood ( tissue ) IdKLH manufacture Antileukemia treatment prior begin immunization Antileukemia treatment IdKLH immunization Prior malignancy ( exclude basal cell carcinoma cervical carcinoma situ ) Pregnant lactate Patients know autoimmune disease ( include previously treat autoimmune hemolytic anemia immune thrombocytopenia ) Participation clinical trial investigational agent administer</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2008</verification_date>
	<keyword>B-Cll</keyword>
</DOC>